Alzheimer’s Drug Slows Cognitive Decline in Key Study
Biogen and Eisai reported the finding from a large late-stage clinical trial of lecanemab, a drug they are developing.
Full Article
Alzheimer’s Drug Slows Cognitive Decline in Key Study
NYTimes.com
0 shares
1 views
You might like
Related news coverage
Biogen shares soar on Alzheimer's drug developments
A study found that Biogen's Alzheimer's drug lecanemab reduced cognitive and functional decline by 27% compared to a placebo over..
FOXNews.com
Biogen soars 43% after its Alzheimer's drug helps slow down cognitive decline in late-stage study
JPMorgan estimates the Alzheimer's drug could generate between $6 billion and $10 billion in peak sales.
Business Insider